Dr. Craig Slingluff Jr, MD

• Surgical Oncology

• General Surgery

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Duke University

  Fellowship Hospital, 1988

• Duke University Mc

  Internship Hospital, 1985

• University Of Virginia School Of Medicine

  Medical School, 1984

• University Of Virginia

  Undergraduate School, 1980

• A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma (E1602), 2013-05-07

• A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma, 2015-01-29

• A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer, 2017-11-21

• MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab, 2013-09-18

• Intraoperative Imaging Guidance for Sentinel Node Biopsy in Melanoma Using a Mobile Gamma Camera, 2016-02-21

• Vaccine Strategy in Melanoma, 2019-04-15

• Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis, 2010-08-20

• Impaired enolase 1 glycolytic activity restrains effector functions of tumor infiltrating CD8+ T cells, 2019-01-25

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Total body photography for skin cancer screening, 2014-12-16

• Myeloid Cell Infiltration Correlates with Prognosis in Cholangiocarcinoma and Varies Based on Tumor Location, 2021-09-01

• Amelanotic Melanomas Presenting as Red Skin Lesions: A Diagnostic Challenge with Potentially Lethal Consequences, 2015-05-23

• Vaccines Targeting Helper T Cells for Cancer Immunotherapy, 2017-07-26

• The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides, 2011-10-31

• Differential expression of CD49a and CD49b determines localization and function of tumor-infiltrating CD8+T cells, 2021-02-22

• Cytokines and TLR agonists influence the expression of retention integrins CD49a, CD49b and CD103 by T cells, 2015-11-04

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Proliferating CD8+T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma, 2021-12-01

• Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature, 2016-12-20

• Immunotype and Immunohistologic Characteristics of Tumor Infiltrating Immune Cells are Associated with Clinical Outcome in Metastatic Melanoma, 2012-01-19

• Molecular insights on the peripheral and intra-tumoral effects of systemic high dose rIL-2 (Aldesleukin) administration for the treatment of metastatic melanoma, 2011-10-05

• Defining the effects of age and gender on clinical immune response to cancer vaccination, 2014-11-06

• Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis, 2009-07-07

• Heterogeneity of CD8+tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies, 2016-10-21

• Defining the Effects of Age and Gender on Immune Response and Outcomes to Melanoma Vaccination: A Retrospective Analysis of a Single-Institution Clinical Trials' Experience, 2015-09-21

• Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis, 2019-08-07

• Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups, 2011-10-05

• Activation, Dysfunction and Retention of T Cells in Vaccine Sites after Injection of Incomplete Freund's Adjuvant, With or Without Peptide, 2013-05-09

• Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test, 2017-08-29

• A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer, 2015-11-04

• Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin, 2005-10-28

• An activation to memory differentiation trajectory of tumor infiltrating lymphocytes informs metastatic melanoma outcomes, 2022-05-09

• Melanoma and immunotherapy bridge 2015 Naples, Italy. 1-5 December 2015, 2016-07-25

• Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI sponsored trials, 2011-08-30

• Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab, 2017-10-12

• "Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry”, 2019-06-29

• IMMUNOGENICITY FOR CD8+ AND CD4+ T CELLS OF TWO FORMULATIONS OF AN INCOMPLETE FREUND'S ADJUVANT FOR MULTIPEPTIDE MELANOMA VACCINES, 2011-10-31

• An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0, 2018-05-30

• Two Patients with Hailey-Hailey Disease, Multiple Primary Melanomas, and Other Cancers, 2016-08-20

• Evaluation of camera-based freehand SPECT in preoperative sentinel lymph node mapping for melanoma patients, 2020-11-11

• Immunologic Hierarchy, Class II MHC Promiscuity, and Epitope Spreading of a Melanoma Helper Peptide Vaccine, 2014-04-23

• Melanoma Trials that Defined Surgical Management: Overview of Trials that Established NCCN Margin Guidelines, 2021-10-12

• Characteristics of immune memory and effector activity to cancer-expressed MHC class I phosphopeptides differ in healthy donors and ovarian cancer patients, 2021-08-19

• TLR2/6 agonists and IFN? synergize to induce melanoma cells to produce T-cell recruiting chemokines, 2013-11-07

• IMMUNE CELL INFILTRATION AND TERTIARY LYMPHOID STRUCTURES AS DETERMINANTS OF ANTI-TUMOR IMMUNITY, 2018-01-15

• Surgical Management of the Patient with Metastatic Melanoma to the Heart, 2013-02-13

• Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63), 2021-01-21

• Utility of Sentinel Lymph Node Biopsy for Solitary Dermal Melanomas, 2015-02-24

• A Case of Spontaneous Systemic Immunity to Melanoma Associated with Cure after Amputation For Extensive Regional Recurrence, 2013-05-12

• IDO1 Expression in Melanoma Metastases is Low and Associated with Improved Overall Survival, 2021-06-01

• T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins, 2014-02-01

• Design, Development, and Evaluation of a Novel Retraction Device for Gallbladder Extraction During Laparoscopic Cholecystectomy, 2013-07-30

• Patterns of immune cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors, 2019-05-27

• Tailoring early-phase clinical trial design to address multiple research objectives, 2019-12-05

• A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers", 2008-12-23

• Flexible Phase I-II design for partially ordered regimens with application to therapeutic cancer vaccines, 2019-06-04

• Progress and controversies in developing cancer vaccines, 2005-04-29

• The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling, 2022-03-11

• Dissecting the treatment-naive ecosystem of human melanoma brain metastasis, 2022-07-07

• EFFECT OF GM-CSF ON CIRCULATING CD8+AND CD4+T CELL RESPONSES TO A MULTIPEPTIDE MELANOMA VACCINE: OUTCOME OF A MULTICENTER RANDOMIZED TRIAL, 2009-11-10

• Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and Cutaneous Lymphocyte Antigen expression by tumor antigen-specific CD8 T cells, 2013-09-16

• Comprehensive analysis of RTK activation in human melanomas reveals autocrine signaling through IGF-1R, 2011-02-02

• Vaccines, adjuvants and dendritic cell activators - Current Status and Future Challenges, 2015-06-03

• Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series, 2020-09-23

• Academic or community practice? What is driving decision-making and career choices, 2018-06-19

• Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+myeloid cell infiltrates, 2021-08-28

• A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes, 2014-07-15

• Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival, 2015-05-12

• Childhood Cancer Survivors Face Markedly Worse Overall Survival after Diagnosis with Breast Cancer, Melanoma, or Colorectal Cancer, 2021-03-31

• Outcomes of Single Node Excision Compared with Lymph Node Dissection for Patients with Clinical Stage III N1b Cutaneous Melanoma, 2023-01-16

• Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma, 2022-07-23

• Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers, 2011-05-10

• The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis, 2020-03-22

• VEGFR-2 Expression in Human Melanoma: Revised Assessment, 2011-05-05

• CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer, 2017-12-29

• Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues, 2020-10-27

• Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma, 2014-05-20

• Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma, 2015-09-25

• A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients, 2019-06-27

• Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines, 2008-10-16

• The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines, 2008-12-04

• Antibody response to melanoma helper-peptide vaccine correlates with survival, 2013-11-07

• Localization of the sentinel lymph node in melanoma without blue dye, 2015-05-15

• Updates in adjuvant systemic therapy for melanoma, 2018-11-27

• MHC-restricted phosphopeptides derived from Insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer, 2014-10-08

• Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma, 2014-05-13

• Apoptosis of CD4+CD25highT cells in response to Sirolimus requires activation of T Cell Receptor and is modulated by IL-2, 2008-10-08

• TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10, 2015-05-29

• From bench to bedside a comprehensive review of pancreatic cancer immunotherapy, 2016-03-15

• Evaluation of Molecular Markers of Mesenchymal Phenotype in Melanoma, 2011-11-09

• Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies, 2017-08-29

• Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer, 2018-01-04

• Phospho-ß-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2., 2021-06-17

• Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures, 2018-03-20

• Conserved interferon-? signaling drives clinical response to immune checkpoint blockade therapy in melanoma, 2020-09-10

• Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study, 2017-05-15

• Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases, 2016-08-13

• Erratum to: Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test, 2017-10-05

• Long-Term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma, 2015-11-03

• Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine, 2015-11-04

• Intratumoral interferon-gamma increases chemokine production but fails to increase T-cell infiltration of human melanoma metastases, 2016-08-13

• A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites, 2015-11-18

• MULTI-PEPTIDE VACCINES VIALED AS PEPTIDE MIXTURES CAN BE STABLE REAGENTS FOR USE IN PEPTIDE-BASED IMMUNE THERAPIES, 2009-02-08

• TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling, 2014-11-06

• INFRARED THERMOGRAPHY OF CUTANEOUS MELANOMA METASTASES, 2012-09-27

• Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma, 2015-05-23

• A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes, 2014-11-06

• Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts, 2021-07-20

• A nano-enhanced vaccine for metastatic melanoma immunotherapy, 2022-07-07

• Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function, 2011-03-08

• Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology, 2009-06-17

• A multi-epitope melanoma helper peptide vaccine durably increases Th1 cytokine production by responding lymphocytes, 2013-11-07

• Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma, 2010-12-14

• Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials, 2010-07-01